Arsenic trioxide
Arsenic trioxide.JPG

Arsenic trioxide

CLINICAL USE

Antineoplastic agent: Acute promyelocytic leukaemia (APL)

DOSE IN NORMAL RENAL FUNCTION

150 mcg/kg daily until remission occurs Consolidation: 150 mcg/kg daily for 5 days per week for 25 doses spread over up to 5 weeks (to start 3–4 weeks after completion of induction)

PHARMACOKINETICS

  • Molecular weight                           : 197.8
  • %Protein binding                           : 96% bound to haemoglobin
  • %Excreted unchanged in urine     : 1–8
  • Volume of distribution (L/kg)       : 4 litres
  • half-life – normal/ESRD (hrs)      : 92/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Reduce dose, use with caution
  • 10 to 20     : Reduce dose, use with caution
  • <10           : Reduce dose, use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     : Dialysed. Dose as in GFR
  • <10           : mL/ min
  • HDF/high flux   : Dialysed. Dose as in GFR
  • <10           : mL/ min
  • CAV/VVHD      : Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs Use with care in combination with other drugs known to cause QT interval prolongation

    ADMINISTRATION

    Reconstition

    Route

    IV

    Rate of Administration

    Over 1–4 hours

    Comments

    Dilute with 100–250 mL glucose 5% or sodium chloride 0.9%

    OTHER INFORMATION

  • Can cause QT interval prolongation and hypokalaemia
  • Arsenic trioxide is under investigation for other conditions, e.g. multiple myeloma, acute myeloid leukaemias and myelodysplastic syndromes
  • Intensive monitoring is required
  • Renal excretion is the main route of elimination; can accumulate in renal impairment
  • Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails. Trivalent forms of arsenic are methylated in humans and mostly excreted in urine. In APL patients, daily administration of 0.15 mg/kg/day of arsenic trioxide resulted in an approximate 4-fold increase in the urinary excretion of arsenic after 2 to 4 weeks of continuous dosing, when compared to baseline values



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs